{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
alpha-tocopherol acetate
to a specific field?
Class (Stereo):
CHEMICAL (ABSOLUTE)
Detorubicin is a semi-synthetic derivative of the anthracycline antineoplastic antibiotic. It intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Detorubicin is less toxic than daunorubicin. Although it showed some clinical activity, the drug appeared to have no particular advantage over doxorubicin except for demonstrated activity against malignant melanoma. Unfortunately, detorubicin clearly has cardiac toxicity – in clinical trial, one patient developed congestive heart failure and other patients revealed endomyocardial biopsy evidence of cardiac toxicity.
Class (Stereo):
CHEMICAL (UNKNOWN)
Deriglidole was reported to inhibit alpha 2-adrenoceptors and ATP-sensitive K+ channels in mouse pancreatic B-cells, and to increase insulin release. The effects of deriglidole are stereoselective on alpha 2-adrenoceptors, but not on ATP-sensitive K+ channels of pancreatic B-cells. Deriglidole had been in phase II clinical trial for the treatment of diabetes mellitus type II in France. However, the study was discontinued.
Status:
Investigational
Source:
NCT00538343: Phase 2 Interventional Terminated Brain Metastases
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Berubicin, an anthracycline derivative, is a DNA binding agent and potent topoisomerase II poison. Reata Pharmaceuticals were developing it as a treatment for brain cancer as it can breach the blood-brain barrier. It had also been in early clinical trials for the treatment of lung cancer and malignant gliomas. However, studies have been terminated. In October 2006, it was granted orphan drug designation from the FDA for the treatment of malignant gliomas. According to a CNS Pharmaceuticals media release in April 2018, berubicin will be studied for glioblastoma patients, these investigations will be funded in part by an equity crowdfunding campaign.
Status:
Investigational
Source:
NCT00684710: Phase 1 Interventional Completed Alzheimer Disease
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Wyeth was developing the small molecule plasminogen activator inhibitor-1 (PAI-1) antagonist aleplasinin for the treatment of Alzheimer's disease in the US. PAZ-417 inhibits PAI-I (Plasminogen activator inhibitor-1), thereby increasing the activation of plasminogen to form plasmin. There is some evidence that plasmin can increase the cleavage of amyloid precursor protein at the alpha cleavage site, which could reduce the formation or increase the clearance of amyloid beta, a suspected culprit in Alzheimer's disease. However, it`s development for Alzheimer's disease treatment was discontinued.
Status:
Investigational
Source:
NCT00389792: Phase 2 Interventional Completed Atrial Fibrillation
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Budiodarone is a chemical analog of amiodarone with mixed ion channel electrophysiological activity. Budiodarone was developed to capitalize on the proven efficacy of amiodarone and to avoid its side effects. Budiodarone has a short plasma half-life (7 h) and a lower volume of distribution (13 L/kg). It is cleared from the body in 48 h. Like amiodarone, Budiodarone has balanced, multiple cardiac ion channel inhibiting activity, giving it properties of all four Vaughan Williams antiarrhythmic drug classes. Budiodarone, unlike amiodarone, undergoes rapid metabolism by plasma and tissue esterases. In clinical trials, Budiodarone effectively reduces the number and duration of atrial tachycardia/atrial fibrillation episodes.
Class (Stereo):
CHEMICAL (RACEMIC)
Elucaine is local anesthetic and anti-ulcerative agent, acting as a gastric muscarinic acetylcholine receptor antagonist.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Eflucimibe is a new and potent Acyl coenzyme A:cholesterol acyltransferases inhibitor. Eflucimibe effectively decreased plasma cholesterol in cholesterol-fed animals. In animal models, drug restores normolipodemia in endogenous hypercholesterolemic rabbits and prevents the progression of atherosclerosis by decreasing the number of macrophages in the foam cells. Eflucimibe has been in phase II clinical trials for the treatment of atherosclerosis and hyperlipidemia. However, this research has been discontinued.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Edifolone (SC-35135) is a structurally unique class Ia antiarrhythmic agent. It acts as a sodium channel antagonist. Edifolone development has been discontinued.
Status:
Investigational
Source:
INN:alphamethadol [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Alphamethadol is a synthetic opioid analgesic. Alphamethadol is composed of two isomers itself, L-α-methadol, and D-α-methadol. L-α-methadol is an important active metabolite of levacetylmethadol (LAAM), a medication therapy for individuals addicted to opiates that provides an alternative to methadone. Isomers of Alphamethadol bind to and activate the μ-opioid receptor; they are active as opioid analgesics.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Bolazine is a synthetic anabolic steroid that uses as the ester prodrug bolazine capronate.
